Among those ICI drugs approved by America Food and Drug Administration (FDA), nivolumab and pembrolizumab are PD-1 inhibitors, atezolimab is a programmed cell death-ligand 1 (PD-L1) inhibitor.[12] Sintilimab, a PD-1 inhibitor approved in China for the treatment of classical Hodgkin lymphoma, is still undergoing phase I, II and III development for use in various solid tumors including NSCLC in China.[8]. This evidence concerns the gene CD274 and Hodgkins lymphoma.